Productive and reproductive performance of rabbits does as affected by bee pollen and/or propolis, inulin and/or mannan-oligosaccharides

[EN] The aim of the paper was to compare the effect of prebiotics (inulin and/or mannan-oligosaccharides, MOS) and bee products (bee pollen and/or propolis) on productive and reproductive performance of rabbit does. Seventy nulliparous V-line female rabbits were distributed among 7 groups. The groups were fed the same diet and received no supplements (control group), natural molecules (bee pollen and/or propolis) at 200 mg/kg body weight (BW) or prebiotics (inulin and/or MOS) at 35 mg/kg BW. Productive, reproductive, biochemical and haematological traits were investigated. Bee pollen with propolis significantly increased body weight gain of does 1 wk after mating (3.53%), decreased feed intake (4.49%) and caused larger litter size (39.4%), heavier body weight of litter (17.7%), a greater number of kits born alive (48.7%), higher weight of kits (87.81%) at 28 d of age, higher milk yield (43.6%) and more favourable milk conversion ratio (31.6%). Moreover, bee pollen with propolis had significantly increased plasma total protein (43.1%), albumin (45.7%), globulin (41.0) and progesterone (60.5%), and had a significantly decreased plasma cholesterol (31.1%), aspartate aminotransferase/alanine aminotransferase ratio (20.3%) compared to the control group. Does treated with growth promoters had significantly fewer services per conception (22%) and greater fertility rate (21%) compared to the control group. Inulin with or without MOS significantly increased plasma glucose (49.9 and 50%, respectively) and feed cost (90.2%) compared to the control group. Supplementation of MOS or bee pollen with or without propolis had significantly greater relative economic efficiency (61.9, 55.1 and 27.1%, respectively) than the control group. MOS and bee pollen with or without propolis are able to improve productive and reproductive performance and economic efficiency of rabbit does in comparison to the unsupplemented group.Attia, Y.; Bovera, F.; El-Tahawy, W.; El-Hanoun, A.; Al-Harthi, M.; Habiba, H. (2015). Productive and reproductive performance of rabbits does as affected by bee pollen and/or propolis, inulin and/or mannan-oligosaccharides. World Rabbit Science. 23(4):273-282. doi:10.4995/wrs.2015.3644.SWORD27328223

Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19: A fiction, hope or hype? An updated review

In December 2019, the novel coronavirus disease pandemic (COVID-19) that began in China had infected so far more than 109,217,366 million individuals worldwide and accounted for more than 2,413,912 fatalities. With the dawn of this novel coronavirus (SARS-CoV-2), there was a requirement to select potential therapies that might effectively kill the virus, accelerate the recovery, or decrease the case fatality rate. Besides the currently available antiviral medications for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), the chloroquine/hydroxychloroquine (CQ/HCQ) regimen with or without azithromycin has been repurposed in China and was recommended by the National Health Commission, China in mid-February 2020. By this time, the selection of this regimen was based on its efficacy against the previous SARS-CoV-1 virus and its potential to inhibit viral replication of the SARS-CoV-2 in vitro. There was a shortage of robust clinical proof about the effectiveness of this regimen against the novel SARS-CoV-2. Therefore, extensive research effort has been made by several researchers worldwide to investigate whether this regimen is safe and effective for the management of COVID-19. In this review, we provided a comprehensive overview of the CQ/HCQ regimen, summarizing data from in vitro studies and clinical trials for the protection against or the treatment of SARS-CoV-2. Despite the initial promising results from the in vitro studies and the widespread use of CQ/HCQ in clinical settings during the 1st wave of COVID-19, current data from well-designed randomized controlled trials showed no evidence of benefit from CQ/HCQ supplementation for the treatment or prophylaxis against SARS-CoV-2 infection. Particularly, the two largest randomized controlled trials to date (RECOVERY and WHO SOLIDARITY trials), both confirmed that CQ/HCQ regimen does not provide any clinical benefit for COVID-19 patients. Therefore, we do not recommend the use of this regimen in COVID-19 patients outside the context of clinical trials

Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

BACKGROUND: Assessments of age-specific mortality and life expectancy have been done by the UN Population Division, Department of Economics and Social Affairs (UNPOP), the United States Census Bureau, WHO, and as part of previous iterations of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Previous iterations of the GBD used population estimates from UNPOP, which were not derived in a way that was internally consistent with the estimates of the numbers of deaths in the GBD. The present iteration of the GBD, GBD 2017, improves on previous assessments and provides timely estimates of the mortality experience of populations globally. METHODS: The GBD uses all available data to produce estimates of mortality rates between 1950 and 2017 for 23 age groups, both sexes, and 918 locations, including 195 countries and territories and subnational locations for 16 countries. Data used include vital registration systems, sample registration systems, household surveys (complete birth histories, summary birth histories, sibling histories), censuses (summary birth histories, household deaths), and Demographic Surveillance Sites. In total, this analysis used 8259 data sources. Estimates of the probability of death between birth and the age of 5 years and between ages 15 and 60 years are generated and then input into a model life table system to produce complete life tables for all locations and years. Fatal discontinuities and mortality due to HIV/AIDS are analysed separately and then incorporated into the estimation. We analyse the relationship between age-specific mortality and development status using the Socio-demographic Index, a composite measure based on fertility under the age of 25 years, education, and income. There are four main methodological improvements in GBD 2017 compared with GBD 2016: 622 additional data sources have been incorporated; new estimates of population, generated by the GBD study, are used; statistical methods used in different components of the analysis have been further standardised and improved; and the analysis has been extended backwards in time by two decades to start in 1950. FINDINGS: Globally, 18·7% (95% uncertainty interval 18·4–19·0) of deaths were registered in 1950 and that proportion has been steadily increasing since, with 58·8% (58·2–59·3) of all deaths being registered in 2015. At the global level, between 1950 and 2017, life expectancy increased from 48·1 years (46·5–49·6) to 70·5 years (70·1–70·8) for men and from 52·9 years (51·7–54·0) to 75·6 years (75·3–75·9) for women. Despite this overall progress, there remains substantial variation in life expectancy at birth in 2017, which ranges from 49·1 years (46·5–51·7) for men in the Central African Republic to 87·6 years (86·9–88·1) among women in Singapore. The greatest progress across age groups was for children younger than 5 years; under-5 mortality dropped from 216·0 deaths (196·3–238·1) per 1000 livebirths in 1950 to 38·9 deaths (35·6–42·83) per 1000 livebirths in 2017, with huge reductions across countries. Nevertheless, there were still 5·4 million (5·2–5·6) deaths among children younger than 5 years in the world in 2017. Progress has been less pronounced and more variable for adults, especially for adult males, who had stagnant or increasing mortality rates in several countries. The gap between male and female life expectancy between 1950 and 2017, while relatively stable at the global level, shows distinctive patterns across super-regions and has consistently been the largest in central Europe, eastern Europe, and central Asia, and smallest in south Asia. Performance was also variable across countries and time in observed mortality rates compared with those expected on the basis of development. INTERPRETATION: This analysis of age-sex-specific mortality shows that there are remarkably complex patterns in population mortality across countries. The findings of this study highlight global successes, such as the large decline in under-5 mortality, which reflects significant local, national, and global commitment and investment over several decades. However, they also bring attention to mortality patterns that are a cause for concern, particularly among adult men and, to a lesser extent, women, whose mortality rates have stagnated in many countries over the time period of this study, and in some cases are increasing

The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. METHODS: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. FINDINGS: Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). INTERPRETATION: The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden

Use of multienzimatic mix on sorghum-soybean meal based ration on hen performance

The use of individual enzymes in the diet of hens has shown an improvement in egg production, and mixtures are now being included to increase feed utilisation and impact on performance in hens. The objective of our study was to evaluate the use of an enzyme blend in a sorghum-soymeal-based ration (protein 17.5% and ME 2900 kcal/kg) on performance. Hens of two lines: Hy-line (n=732) and Bovans white (n=365), aged eighteen weeks, were used to evaluated three treatments (control, Ronozyme blend or Cybenza). The birds were lodged in cages with a density of 485 cm2 per hen (four hens per cage). There were no differences (P>0.05) among enzymatic treatments or their interactions with the hen line on egg yield, egg mass, feed-to-egg ratio, or egg quality. However, the efficiency was higher with Hy-line (P<0.05) and enzymes (P<0.05) but was not affected by the interaction (P>0.05). Based on our results, we concluded that the use of a multi-enzyme mixture in a sorghum-soymeal-based hen feed has a minor effect on performance, regardless of hen genetics

The effects of preparing methods and enzyme supplementation on the utilization of brown marine algae (Sargassum dentifebium) meal in the diet of laying hens

Brown marine algae (BMA; <em>Sargassum dentifebium</em>) were collected from Jeddah on the shores of the Red Sea and sun dried at an average daily temperature of 40°C until constant weight was obtained. Part of the sun dried brown marine algae was subsequently processed by boiling (BBMA;boiled brown marine algae) in water and by autoclaving (ABMA; autoclaved brown marine algae). The SBMA, BBMA and ABMA were included in laying hen diet during weeks 23-42 of age at concentrations of 0.0%, 3.0% and 6.0%. The diets were given with or without enzyme supplementation. This resulted in 3 (preparation methods) × 2 (concentrations of supplemented BMA, i.e. 3 and 6 %) × 2 (with and without enzyme supplementation) diet programs plus two control groups (with and without enzyme supplementation) for a total of 14 treatments. Each treatment was represented by six replicates of five hens each. Sun dried or autocalved brown marine algae at 3% without enzyme supplementation in the laying hen diet could be fed to laying hens without any adverse effect on laying performance. However, enzyme supplementation to a diet containing 6% autocalved brown marine algae improved productive performance and eggshell quality